Antimicrobial resistance research

Research initiatives to develop new treatments to tackle antimicrobial resistance (AMR) will receive a cash injection of up to £39 million from the UK government. AMR – where bacteria have evolved so much that antibiotics and other current treatments are no longer effective against infections – is a silent killer costing millions of lives across the world a year, with one in five of these deaths in children under the age of five. Of this new funding package, up to £24 million over four years has been awarded to bolster the UK’s partnership with CARB-X – a global AMR research initiative – to support the continued early development of new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world.